PMC:7426526 / 21665-23000 JSONTXT

{"project":"TEST0","denotations":[{"id":"32849491-88-94-3396301","span":{"begin":192,"end":194},"obj":"[\"26621583\"]"},{"id":"32849491-92-99-3396302","span":{"begin":196,"end":199},"obj":"[\"25909162\"]"},{"id":"32849491-97-104-3396303","span":{"begin":201,"end":204},"obj":"[\"25789008\"]"},{"id":"32849491-102-109-3396304","span":{"begin":206,"end":209},"obj":"[\"12511867\"]"},{"id":"32849491-184-191-3396305","span":{"begin":396,"end":399},"obj":"[\"27507615\"]"},{"id":"32849491-86-93-3396306","span":{"begin":488,"end":491},"obj":"[\"26840024\"]"},{"id":"32849491-152-159-3396307","span":{"begin":646,"end":649},"obj":"[\"28116522\"]"},{"id":"32849491-120-127-3396308","span":{"begin":772,"end":775},"obj":"[\"25979842\"]"},{"id":"32849491-144-151-3396309","span":{"begin":922,"end":925},"obj":"[\"19415765\"]"},{"id":"32849491-153-160-3396310","span":{"begin":1081,"end":1084},"obj":"[\"30692202\"]"},{"id":"32849491-152-159-3396311","span":{"begin":1239,"end":1242},"obj":"[\"30798450\"]"},{"id":"32849491-85-92-3396312","span":{"begin":1330,"end":1333},"obj":"[\"24618343\"]"}],"text":"CD44 is a biomarker which is not only expressed in solid but also in hematological cancers (see below). Its expression is associated with increased proliferation, self-renewal and metastasis (61, 149, 462, 463). For example, in colorectal cancers, expression of CD44/CD166 characterizes a cell population able to form tumor spheres, suggesting anchorage-independent proliferation of these cells (333). In other studies, CD44high/CD133high cells showed increased tumorigenic capabilities (334). Also in breast cancers, the percentage of CD44+/CD24−/CK+/CD45− cells was shown to be increased in malignant lesions compared to non-malignant lesions (139). A significant decrease in proliferation and migration of breast cancer cells was observed after the knock-down of CD44 (140). In gastric cancers, the knock-down of CD44 reduced sphere formation and caused decreased tumor growth in severe combined immunodeficiency mice (246). In many tumors (e.g., breast and liver), CD44 is expressed as isoform and its expression has been associated with increased cancer stem cell properties (141). In lung cancers, CD44v9 expression correlates significantly with early-stage lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations (464). Variants of CD44 are also expressed in gastric cancers and promote tumor initiation (248)."}

{"project":"MyTest","denotations":[{"id":"32849491-26621583-34970681","span":{"begin":192,"end":194},"obj":"26621583"},{"id":"32849491-25909162-34970682","span":{"begin":196,"end":199},"obj":"25909162"},{"id":"32849491-25789008-34970683","span":{"begin":201,"end":204},"obj":"25789008"},{"id":"32849491-12511867-34970684","span":{"begin":206,"end":209},"obj":"12511867"},{"id":"32849491-27507615-34970685","span":{"begin":396,"end":399},"obj":"27507615"},{"id":"32849491-26840024-34970686","span":{"begin":488,"end":491},"obj":"26840024"},{"id":"32849491-28116522-34970687","span":{"begin":646,"end":649},"obj":"28116522"},{"id":"32849491-25979842-34970688","span":{"begin":772,"end":775},"obj":"25979842"},{"id":"32849491-19415765-34970689","span":{"begin":922,"end":925},"obj":"19415765"},{"id":"32849491-30692202-34970690","span":{"begin":1081,"end":1084},"obj":"30692202"},{"id":"32849491-30798450-34970691","span":{"begin":1239,"end":1242},"obj":"30798450"},{"id":"32849491-24618343-34970692","span":{"begin":1330,"end":1333},"obj":"24618343"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"CD44 is a biomarker which is not only expressed in solid but also in hematological cancers (see below). Its expression is associated with increased proliferation, self-renewal and metastasis (61, 149, 462, 463). For example, in colorectal cancers, expression of CD44/CD166 characterizes a cell population able to form tumor spheres, suggesting anchorage-independent proliferation of these cells (333). In other studies, CD44high/CD133high cells showed increased tumorigenic capabilities (334). Also in breast cancers, the percentage of CD44+/CD24−/CK+/CD45− cells was shown to be increased in malignant lesions compared to non-malignant lesions (139). A significant decrease in proliferation and migration of breast cancer cells was observed after the knock-down of CD44 (140). In gastric cancers, the knock-down of CD44 reduced sphere formation and caused decreased tumor growth in severe combined immunodeficiency mice (246). In many tumors (e.g., breast and liver), CD44 is expressed as isoform and its expression has been associated with increased cancer stem cell properties (141). In lung cancers, CD44v9 expression correlates significantly with early-stage lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations (464). Variants of CD44 are also expressed in gastric cancers and promote tumor initiation (248)."}

{"project":"2_test","denotations":[{"id":"32849491-26621583-34970681","span":{"begin":192,"end":194},"obj":"26621583"},{"id":"32849491-25909162-34970682","span":{"begin":196,"end":199},"obj":"25909162"},{"id":"32849491-25789008-34970683","span":{"begin":201,"end":204},"obj":"25789008"},{"id":"32849491-12511867-34970684","span":{"begin":206,"end":209},"obj":"12511867"},{"id":"32849491-27507615-34970685","span":{"begin":396,"end":399},"obj":"27507615"},{"id":"32849491-26840024-34970686","span":{"begin":488,"end":491},"obj":"26840024"},{"id":"32849491-28116522-34970687","span":{"begin":646,"end":649},"obj":"28116522"},{"id":"32849491-25979842-34970688","span":{"begin":772,"end":775},"obj":"25979842"},{"id":"32849491-19415765-34970689","span":{"begin":922,"end":925},"obj":"19415765"},{"id":"32849491-30692202-34970690","span":{"begin":1081,"end":1084},"obj":"30692202"},{"id":"32849491-30798450-34970691","span":{"begin":1239,"end":1242},"obj":"30798450"},{"id":"32849491-24618343-34970692","span":{"begin":1330,"end":1333},"obj":"24618343"}],"text":"CD44 is a biomarker which is not only expressed in solid but also in hematological cancers (see below). Its expression is associated with increased proliferation, self-renewal and metastasis (61, 149, 462, 463). For example, in colorectal cancers, expression of CD44/CD166 characterizes a cell population able to form tumor spheres, suggesting anchorage-independent proliferation of these cells (333). In other studies, CD44high/CD133high cells showed increased tumorigenic capabilities (334). Also in breast cancers, the percentage of CD44+/CD24−/CK+/CD45− cells was shown to be increased in malignant lesions compared to non-malignant lesions (139). A significant decrease in proliferation and migration of breast cancer cells was observed after the knock-down of CD44 (140). In gastric cancers, the knock-down of CD44 reduced sphere formation and caused decreased tumor growth in severe combined immunodeficiency mice (246). In many tumors (e.g., breast and liver), CD44 is expressed as isoform and its expression has been associated with increased cancer stem cell properties (141). In lung cancers, CD44v9 expression correlates significantly with early-stage lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations (464). Variants of CD44 are also expressed in gastric cancers and promote tumor initiation (248)."}